drugset / Trial / NCT05675800
Psilocybin for Major Depressive Disorder
Phase 2
Withdrawn
Washington University School of Medicine
National Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to assess the effectiveness of psilocybin for the treatment of Major Depressive Disorder and potential therapeutic mechanisms. Enrolled participants will receive a single active dose of psilocybin, or a dose considered high enough to treat depression, administered orally with accompanying psychological support.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2025-01-01
- Completion
- 2025-03-31
Outcome
Outcome not reported
Stopped: “Resident who was tasked with coordinating this study is no longer able to do so.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | — | Oral |